Navigation Links
Groundbreaking Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy
Date:8/27/2013

Milwaukee, WI (PRWEB) August 27, 2013

The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma has been released by the Society for Immunotherapy of Cancer (SITC) and published online by Nature Reviews Clinical Oncology. Essentially a road map for using immunotherapy to treat patients with melanoma, this consensus statement known as the “Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” provides patients and physicians alike with expert evidence-based recommendations for the use of different immunotherapies including interferon-a2, pegylated interferon, interleukin-2 (IL-2) and ipilimumab. Recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapy, are also provided in this statement.

“Cancer immunotherapy is a rapidly advancing form of cancer treatment that has induced durable therapeutic responses in a subset of patients with advanced melanoma,” Michael Atkins, MD, Georgetown-Lombardi Comprehensive Cancer Center and a co-author on the paper said. “Current data suggests that cancer immunotherapy is being underutilized and many patients who might benefit from immunotherapy are not given the opportunity in the optimal setting. The goal of these guidelines is to change that and to provide a readily available and comprehensive resource about how and when to consider immunotherapy for patients with melanoma.”

Prior to the consensus statement’s publication, the lack of evidence-based guidelines in the field created obstacles and discord for practicing oncologists in the treatment of patients with melanoma. Now, this statement provides the best available evidence and consensus thinking for those interested in pursuing treatment with immunotherapy.

“The SITC consensus statement addresses the knowledge gaps and creates a standard set of guiding principles for oncologists set forth for the effective and efficient application of cancer immunotherapy for patients with melanoma,” Howard L. Kaufman, MD, FACS, Rush University Medical Center and corresponding author on the paper said. “The group of authors who developed this statement considered the strength of the evidence for key issues in the field and provided consensus recommendations in these areas; especially where data was weak or missing.”

This consensus statement was created from work done by the SITC Cancer Immunotherapy Guidelines (CIG) Task Force established in 2010 and made up of more than 30 experts in the field of melanoma. The task force utilized the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for the consensus statement. However, as cancer immunotherapy continues to rapidly develop, the SITC Melanoma CIG Task Force will update the consensus statement as new findings and results from on-going clinical trials or as the approval of drugs from the FDA for the treatment of melanoma are released.

To read “The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” visit: http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2013.153.html.

For more information on the consensus statement and the Society for Immunotherapy of Cancer, visit: http://www.sitcancer.org/about-sitc/initiatives/cancer-immunotherapy-guidelines.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11066759.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
4. Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
5. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
6. JTCC researchers play important role in groundbreaking study that may change transplant practices
7. MyPuress Releases Details About Groundbreaking New Product
8. Rectal microbicide research takes giant leap forward with groundbreaking educational video
9. Skin Authority Creates One-of-a-Kind Solution for the One Billion People Worldwide Who are Vitamin D Deficient -- Groundbreaking Launch of "Inside Out" System
10. Groundbreaking Training Video Prepares Surgical Team to Become Safest in the U.S.
11. Groundbreaking UK study shows key enzyme missing from aggressive form of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , ... May 04, 2016 , ... Dr. Elyson and ... tooth removal surgery at their office. Wisdom tooth removal, a common dental procedure, is ... problematic, they often are improperly erupted, resulting in risks of complications. By providing wisdom ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... that supports cellular and metabolic health. This synergistic combination of omega-3 fatty acids ... along with 150 mg of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). ...
(Date:5/4/2016)... ... 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an ... same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, ... the same day as her in-office consultation and eye exam. Francesca’s eyesight was restored ...
(Date:5/4/2016)... ... May 04, 2016 , ... Pharmacy Times ... that it was chosen as the Pharmaceutical News Provider of the Year in ... acknowledge the hard work and dedication of community members who strive to make ...
(Date:5/4/2016)... ... 04, 2016 , ... Bayco Products has announced the introduction ... flashlights in models NSP-9842XL and NSR-9844XL . , First previewed at SHOT ... 2 included CR-123 batteries to produce up to 650 lumens in a variety ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... heute bekannt, dass sie einen entscheidenden Meilenstein ... haben: Ein Aufruf zum Handeln, um Patientenresultate ... Veröffentlichung trägt zu Fortschritten im Verständnis der ... hervor, ein Bewusstsein für Hepatische Enzephalopathie in ...
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.8 India 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India ... , registered the fastest GDP growth during the first decade of the 21 ... in Brazil and Russia , along ...
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
Breaking Medicine Technology: